RAsmo: Effect of Smoking on Pain and Atherosclerosis in Patients With Rheumatoid Arthritis

Sponsor
Vastra Gotaland Region (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03449589
Collaborator
(none)
1,000
1
168
6

Study Details

Study Description

Brief Summary

Primary aim: examine a possible connection between cigarette smoking, disease activity and perceived pain in patients with rheumatoid arthritis.

Secondary aim: Evaluate cardiovascular risk in patients with rheumatoid arthritis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study will recruit patients with rheumatoid arthritis (age 20-60 years) at rheumatology clinics in Västra Götaland. All patients meeting the inclusion criteria will be informed of the study in a letter and later contacted by the study coordinator and if interested booked for a study visit at the rheumatology clinic. At the study visit the patients will meet with rheumatologist for clinical examination of their joints and tenderpoints. An algometer is used for objective quantification of the patients pain sensitivity. Questionnaire regarding medical treatment, other diseases, smoking habits, subjective pain, fatigue, anxiety and depression, ability to work and ability to perform everyday activities are filled out by the patient.

    Height, weight, blood pressure, blood, urine and fat biopsy will be collected for analyse.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Effect of Smoking on Pain and Atherosclerosis in Patients With Rheumatoid Arthritis
    Actual Study Start Date :
    Nov 1, 2011
    Anticipated Primary Completion Date :
    Nov 1, 2025
    Anticipated Study Completion Date :
    Nov 1, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    Smokers

    RA patients currently smoking

    Former smokers

    RA patients who previously smoked

    Non smokers

    Non smoking RA patients

    Outcome Measures

    Primary Outcome Measures

    1. Disease activity score (DAS 28) [At patient enrollment/study visit]

      Difference in disease activity score (DAS 28) in smoking vs non-smoking RA-patients Disease activity, DAS28, is calculated using a specific formula based on: number of painful joints out of 28 joints examined number of swollen joints out of 28 joints examined erythrocyte sedimentation rate (ESR) or C reactive protein (CRP) patient's global assessment of disease activity on a 100 mm visual analogue scale (VAS) DAS thresholds: DAS28 lower than 2.6: remission DAS28 below 3.2: low disease activity DAS28 over 3.2 and under 5.1: moderate disease activity DAS28 above 5.1: high disease activity

    2. Pain sensitivity (Pressure Pain Detection Threshold, PPDT) [At patient enrollment/study visit]

      Difference in pain sensitivity in smoking vs non-smoking RA-patients. Testing of of all patients' pressure pain detection threshold (PPDT), i-e pain sensitivity is performed by trained personnel, using an algometer. The algometer is placed bilaterally on the nail of the thumb and on the second metatarsophalangeal joint (MTP2), giving a total of four measured points. A progressively increasing pressure is applied with the algometer and the patients are carefully instructed to signal as soon as the pressure sensation turns into pain (not to withstand the pain) and the algometer is removed. The amount of applied force shown in kPa in the display is reported as the PPDT. The measurements are performed twice for each point and an average value is calculated as the patients' pain sensitivity threshold/pressure pain detection threshold.

    3. Subjective pain perception (VAS) [At patient enrollment/study visit]

      Difference in pain perception in smoking vs non-smoking RA-patients Subjective pain perception is registered by self-reported estimation of pain on a visual analogue scale (VAS) of 100 mm concerning the week preceding the study.

    4. Cardiovascular risk [At patient enrollment/study visit]

      Difference in cardiovascular risk (Framingham score) in smoking vs non-smoking RA-patients The Framingham risk score is a gender-specific algorithm used to estimate the 10-year cardiovascular risk of an individual calculated on the basis of the following: Age Gender Total cholesterol HDL cholesterol Smoker Diabetes Systolic blood pressure Treatment for high blood pressure

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients aged 20-60 years diagnosed with rheumatoid arthritis
    Exclusion Criteria:
    • Other serious physical or mental illness, lack of knowledge in Swedish language making answering the questionnaires impossible

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dept of Rheumatology and Inflammation research Gothenburg Sweden

    Sponsors and Collaborators

    • Vastra Gotaland Region

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Vastra Gotaland Region
    ClinicalTrials.gov Identifier:
    NCT03449589
    Other Study ID Numbers:
    • RÖK
    First Posted:
    Feb 28, 2018
    Last Update Posted:
    May 4, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 4, 2022